Zoryve is a prescription topical medication used to treat three inflammatory skin conditions: plaque psoriasis, atopic dermatitis (eczema), and seborrheic dermatitis. It contains roflumilast, which works by calming overactive immune signaling in the skin. Zoryve comes in two forms, a cream and a foam, with different strengths tailored to each condition.
The Three Conditions Zoryve Treats
Zoryve 0.3% cream is approved for plaque psoriasis in adults and children ages 6 and older. This includes use on sensitive skin folds like the groin, armpits, and under the breasts, areas where many other topical treatments are too harsh for long-term use. A lower-strength version, Zoryve 0.15% cream, is approved for mild to moderate atopic dermatitis in the same age range.
For seborrheic dermatitis, the flaky, red patches that commonly appear on the scalp, face, and chest, Zoryve is available as a 0.3% foam. The foam formulation makes it easier to apply to the scalp and other hair-bearing areas.
How Zoryve Works
Zoryve belongs to a class of drugs called PDE4 inhibitors. Inside your immune cells, an enzyme called PDE4 breaks down a molecule that normally keeps inflammation in check. By blocking that enzyme, Zoryve lets the molecule build up, which dials down the production of inflammatory signals driving redness, scaling, and itching. At the same time, it promotes anti-inflammatory signals. This dual action targets the root immune dysfunction behind all three conditions rather than simply masking symptoms.
How Well It Works for Psoriasis
Zoryve 0.3% cream is applied once daily to affected areas. In clinical trials, the primary measure of success was achieving clear or almost clear skin with at least a 2-point improvement on a standardized severity scale by week 8. The cream is notable for being one of the few topical psoriasis treatments specifically indicated for intertriginous areas, giving people with psoriasis in skin folds a steroid-free option they can use without the thinning and irritation risks that come with long-term steroid use in those sensitive zones.
Results for Atopic Dermatitis
For eczema, the lower-strength 0.15% cream showed meaningful results in just four weeks. In two large clinical trials called INTEGUMENT-1 and INTEGUMENT-2, about 32% and 29% of patients achieved clear or almost clear skin with significant improvement, compared to roughly 15% and 12% on the inactive cream. When looking at any level of clearance, approximately 40% of both children and adults reached clear or almost clear skin by week 4.
The itch relief numbers are equally relevant for daily life. Over 30% of patients in each trial achieved a clinically meaningful reduction in their worst itch scores, and 9 in 10 patients saw at least some improvement at the four-week mark. About 69% of patients reached at least a 50% reduction in their overall eczema severity, a threshold considered clinically meaningful.
Results for Seborrheic Dermatitis
The foam formulation performed strongly in the STRATUM trial. At week 8, nearly 80% of patients using the foam achieved clear or almost clear skin with significant improvement, compared to 58% using the inactive foam. Half of all patients on Zoryve foam reached completely clear skin. These are notably high response rates for a topical treatment, reflecting how well the foam delivers the medication to seborrheic dermatitis patches on the scalp and face.
How to Use It
All formulations of Zoryve are applied once a day. For the cream, you apply a thin layer to affected areas and rub it in completely. There is no limit on which body areas you can treat, and unlike topical steroids, the labeling does not restrict use on the face or skin folds. This simplicity is part of the appeal for people who have previously managed multiple prescriptions for different body areas.
Side Effects
The most common side effects reported in clinical trials, each occurring in at least 1% of patients, include diarrhea, headache, trouble sleeping, pain at the application site, upper respiratory infections, and urinary tract infections. The diarrhea and headache are related to the drug’s mechanism, since PDE4 inhibitors can affect the gut and nervous system even when applied to the skin. For most people these effects are mild, but they distinguish Zoryve from purely topical treatments that stay in the skin.
Who Should Not Use Zoryve
Zoryve is contraindicated in people with moderate to severe liver impairment. Because some of the medication is absorbed through the skin and processed by the liver, impaired liver function can lead to higher-than-intended drug levels in the body. People with mild liver impairment can use it without dose adjustment. Zoryve is not approved for children under 6 years old.